文献速递瓣膜外科

机器人二尖瓣修复术治疗退行性二尖瓣反流

Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation.
PubMed 文献 · Ann Thorac Surg · 2023-08-16

研究分析2015至2021年STS成人心脏外科数据库中61,322例退行性二尖瓣反流修复患者,比较机器人、开胸与胸骨正中切开途径。倾向性匹配后机器人组死亡率与并发症无显著差异,但转换率更低、住院时间更短、30天再入院更少。

要点

  • 机器人二尖瓣修复占比从2015年10.9%升至2021年14.6%。
  • 匹配后机器人组死亡与并发症无显著差异,转换率更低、住院更短、再入院更少。
  • 高容量中心死亡与并发症更低,累积机器人手术达40例时跨过全国均值。

核心结论

  • 机器人二尖瓣修复安全有效,与开胸或胸骨正中切开相比死亡与并发症相当,转换率更低、住院时间更短、30天再入院更少。

研究设计与样本

  • 基于STS成人心脏外科数据库2015至2021年61,322例退行性二尖瓣反流拟行修复患者的分析。
  • 倾向性评分分别匹配5540对机器人vs开胸和6962对机器人vs胸骨正中切开。
  • 结局为手术死亡、死亡与主要并发症复合、术后住院时间和转为二尖瓣置换。

主要发现

  • 7年间116名外科医生在103家医院完成机器人二尖瓣修复。
  • 机器人病例占比从2015年10.9%(949/8712)升至2021年14.6%(1274/8730)。
  • 机器人vs开胸匹配组死亡与并发症无显著差异,转换1.2% vs 3.1%,住院更短、30天再入院更少。
  • 机器人vs胸骨正中切开匹配组死亡与并发症无显著差异,转换1.0% vs 3.7%,住院更短、30天再入院更少。
  • 高容量中心死亡与并发症更低,累积机器人二尖瓣修复达40例时跨过全国平均死亡与并发症水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary national utilization and comparative safety data of robotic mitral valve repair for degenerative mitral regurgitation compared with nonrobotic approaches are lacking. The study aimed to characterize national trends of utilization and outcomes of robotic mitral repair of degenerative mitral regurgitation compared with sternotomy and thoracotomy approaches. METHODS: Patients undergoing intended mitral repair of degenerative mitral regurgitation in The Society of Thoracic Surgeons Adult Cardiac Surgery Database between 2015 and 2021 were examined. Mitral repair was performed in 61,322 patients. Descriptive analyses characterized center-level volumes and outcomes. Propensity score matching separately identified 5540 pairs of robotic vs thoracotomy approaches and 6962 pairs of robotic vs sternotomy approaches. Outcomes were operative mortality, composite mortality and major morbidity, postoperative length of stay, and conversion to mitral replacement. RESULTS: Through the 7-year study period, 116 surgeons across 103 hospitals performed mitral repair robotically. The proportion of robotic cases increased from 10.9% (949 of 8712) in 2015 to 14.6% (1274 of 8730) in 2021. In both robotic-thoracotomy and robotic-sternotomy matched pairs, mortality and morbidity were not significantly different, whereas the robotic approach had lower conversion (1.2% vs 3.1% for robotic-thoracotomy and 1.0% vs 3.7% for robotic-sternotomy), shorter length of stay, and fewer 30-day readmissions. Mortality and morbidity were lower at higher-volume centers, crossing the national mean mortality and morbidity at a cumulative robotic mitral repair case of 40. CONCLUSIONS: Robotic mitral repair is a safe and effective approach and is associated with comparable mortality and morbidity, a lower conversion rate, a shorter length of stay, and fewer 30-day readmissions than thoracotomy or sternotomy approaches.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mori M, Parsons N, Krane M, et al. Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation. Ann Thorac Surg. 2023. PMID: 37595861. doi:10.1016/j.athoracsur.2023.07.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。